PAB Patrys Limited
—Mkt Cap: —P/E: —1d ago
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value9.35M USD
Revenue (TTM)6.21K USD
Gross Profit6.21K USD
Net Income (TTM)-2.08M USD
Revenue/Share0.00 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000PAB9
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.96
EV/Revenue1505.24
P/S1131.16
P/B2.07
EPS (TTM)-0.02
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-5896.41%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-411.16%
ROA-173.27%
Growth
Revenue Growth-93.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.50M USD
CapEx (TTM)—
FCF Margin-12824.21%
FCF Yield—
Net Debt-2.32M USD
Net Debt/EBITDA0.98
Balance Sheet
Debt/Equity—
Current Ratio3.84
Quick Ratio3.77
Book Value/Sh0.01 AUD
Cash/Share0.0060 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.1300 AUD
Target Range0.1300 AUD – 0.1300 AUD
# Analysts1
Ownership
Shares Out.340.73M
Float386.97M
Insiders30.17%
Institutions0.00%
Technical
SMA 500.0319 AUD
SMA 2000.0336 AUD
Beta1.27
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)464.06K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—